Soft tissue sarcoma (STS) is a relatively common tumor in dogs. However, very few canine STS cell lines are available This study aimed to establish a new cell line, STS-YU1, derived from a recurrence of myxosarcoma in an 11-year-old mixed-breed dog. We examined STS-YU1 for cell proliferation, migration, anticancer drug sensitivity, transcriptome analysis using next-generation sequencing (RNA-seq), and tumorigenicity in mice and compared it with previously established STS cell lines, MUMA-G and A72. The cell proliferation and migration of STS-YU1 were higher than MUMA-G although MUMA-G only exhibited tumorigenicity in mice. STS-YU1 showed dose-dependent cytotoxicity to anticancer drugs, but with weak effects. RNA-seq analysis revealed the molecular phenotype of STS-YU1 was different from that of a previously reported cell line, A72. Hence, the use of STS-YU1 would help in efficient drug screening against canine STS .

中文翻译：

---

新型犬软组织肉瘤细胞系的建立及其与其他软组织肉瘤细胞系的特性比较

软组织肉瘤（STS）是狗中相对常见的肿瘤。然而，可用的犬 STS 细胞系很少。这项研究旨在建立一种新的细胞系 STS-YU1，该细胞系源自一只 11 岁混种狗复发的粘液肉瘤。我们检查了 STS-YU1 的细胞增殖、迁移、抗癌药物敏感性、使用下一代测序 (RNA-seq) 进行的转录组分析以及小鼠的致瘤性，并将其与先前建立的 STS 细胞系 MUMA-G 和 A72 进行了比较。尽管MUMA-G仅在小鼠中表现出致瘤性，但STS-YU1的细胞增殖和迁移高于MUMA-G。 STS-YU1对抗癌药物表现出剂量依赖性细胞毒性，但作用较弱。 RNA-seq 分析显示 STS-YU1 的分子表型与之前报道的细胞系 A72 不同。因此，STS-YU1的使用将有助于有效筛选针对犬STS的药物。